Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
2(15%)
Results Posted
57%(4 trials)
Terminated
1(8%)

Phase Distribution

Ph not_applicable
1
8%
Ph early_phase_1
2
15%
Ph phase_3
3
23%
Ph phase_1
3
23%
Ph phase_2
2
15%
Ph phase_4
2
15%

Phase Distribution

5

Early Stage

2

Mid Stage

5

Late Stage

Phase Distribution13 total trials
Early Phase 1First-in-human
2(15.4%)
Phase 1Safety & dosage
3(23.1%)
Phase 2Efficacy & side effects
2(15.4%)
Phase 3Large-scale testing
3(23.1%)
Phase 4Post-market surveillance
2(15.4%)
N/ANon-phased studies
1(7.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

2

trials recruiting

Total Trials

13

all time

Status Distribution
Active(3)
Completed(7)
Terminated(1)
Other(2)

Detailed Status

Completed7
unknown2
Recruiting2
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
2
Success Rate
87.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (15.4%)
Phase 13 (23.1%)
Phase 22 (15.4%)
Phase 33 (23.1%)
Phase 42 (15.4%)
N/A1 (7.7%)

Trials by Status

unknown215%
not_yet_recruiting18%
recruiting215%
completed754%
terminated18%

Recent Activity

Clinical Trials (13)

Drug Details

Intervention Type
DRUG
Total Trials
13